Sunday, December 1, 2019

Biocon Biologics to reduce the cost of human insulin and cancer drugs

The Biocon subsidiary will chart a path that ensures high volumes and lowcosts, unlike competitors, Christiane Hamacher, chief executive of Biocon Biologics told ET. https://ift.tt/2RcdZVI https://ift.tt/eA8V8J
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Tether's USDT stablecoin is set to return to the Bitcoin network through Tether-backed Utexo, which will keep most transaction data off Bitcoin's public ledger (CoinDesk)

CoinDesk : Tether's USDT stablecoin is set to return to the Bitcoin network through Tether-backed Utexo, which will keep most transac...